Table 2.
Vaccination of African green monkeys with b/h PIV3/hMPV F2 generates hMPV neutralizing antibody titers
| Immunizing virus | Day of serum collectiona | Rise in hMPV neutralizing antibody titers (50% Reciprocal log2 ± S.D.) |
|
|---|---|---|---|
| hMPV Ab,c | hMPV Bb,d | ||
| hMPV/NL/1/00 | 28 | 11.1 ± 1.9e | 4.0 ± 0.8e |
| 56 | 10.2 ± 1.5 | 3.7 ± 1.0 | |
| b/h PIV3/hMPV F2 | 28 | 7.1 ± 1.2e | 2.7 ± 1.1e |
| 56 | 8.4 ± 1.2 | 3.9 ± 1.6 | |
| Placebo | 28 | 0.0 ± 0.0 | 1.0 ± 1.3 |
| 56 | 6.8 ± 2.0 | 2.9 ± 1.6 | |
a
Day 28 prior to hMPV/NL/1/00 (Al) challenge and day 56 (4 weeks post-challenge).
b
hMPV/NL/l/00 and hMPV/NL/l/99 represent group A l and B l antigens in the neutralization assays.
c
Average day 1 pre-sera = 2.2 ± 0.9.
d
Average day 1 pre-sera = 5.1 ± 1.4.
e
Neutralization antibody titers between hMPV A and hMPV B antigens is statistically significant (P < 0.05).